标题
Chemotherapeutic inhibitors in the treatment of prostate cancer
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume 15, Issue 1, Pages 11-22
出版商
Informa Healthcare
发表日期
2013-10-25
DOI
10.1517/14656566.2014.852184
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- New treatment options for castration-resistant prostate cancer
- (2013) K. Simondsen et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- New treatment developments applied to elderly patients with advanced prostate cancer
- (2013) Deborah Mukherji et al. CANCER TREATMENT REVIEWS
- New Agents in the Arsenal to Fight Castrate-Resistant Prostate Cancer
- (2013) Erin E. Ezzell et al. Current Oncology Reports
- Use of androgen deprivation therapy in prostate cancer: indications and prevalence
- (2012) Roisin M Connolly et al. ASIAN JOURNAL OF ANDROLOGY
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Docetaxel
- (2012) Kate McKeage DRUGS
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer
- (2012) Sohaib Al-Asaaed et al. Current Oncology Reports
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging treatment options for patients with castration-resistant prostate cancer
- (2011) Daniel George et al. PROSTATE
- Novel options for the treatment of castration-resistant prostate cancer
- (2011) Carsten-H. Ohlmann et al. WORLD JOURNAL OF UROLOGY
- Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
- (2010) M.-L. Zhu et al. CANCER RESEARCH
- Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate Cancer
- (2010) Ryan M. Franke et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
- (2009) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
- (2008) X. Pivot et al. ANNALS OF ONCOLOGY
- Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer
- (2008) Grace L. Lu-Yao JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Docetaxel Plus Prednisolone for the Treatment of Metastatic Hormone-refractory Prostate Cancer: A Multicenter Phase II Trial in Japan
- (2008) S. Naito et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time
- (2008) Philip M. Arlen et al. JOURNAL OF UROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started